The FDA’s weak drug manufacturing oversight is a potentially deadly problem
COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
June 23, 2021 • ~9 min